 So yeah, I I get the last five minutes. I was talking to Deborah Leonard and and I told her I wasn't going to use slides And she said it was important that I set the right precedent So, you know, there's my slide So I think it would be hard for me to sort of make slides on the fly So the things that I have heard are that we need to have better rapid learning systems to capture not just phenotypes, but outcomes And we should learn from each encounter and we should learn from each time clinical decision support fires We should develop systems to figure out what happens next I think one of the things that we've heard is that Cesar has developed and refined guidelines in populations And there is the tension that at least I feel and I think some people feel between guidelines in populations and management of individual patients and families how to engage families is something that I I don't think anybody within the NHGRI Genomic medicine portfolio is dealing with much except for Cesar and perhaps the newborn program The legal and regulatory frameworks are something that is still on the table for Cesar and will continue to be on the On the on the agenda So so those are the things that I think I heard in this session. I'd be I'm open to to correction or change in emphasis, but otherwise We'll move on Okay Great. Thank you very much. I think we are ready for the break and thank you to the first session for keeping us on time and Calling on folks and thank you all. Let's let's come back at 11 o'clock promptly at 11 o'clock for the start of the next session